Abstract
Chalcones constitute a group of phenolic compounds that command an increasing interest on cancer research. Natural chalcones are widespread through the plant kingdom. The most abundant and investigated chalcones are isoliquiritigenin, flavokawain and xanthohumol, which are present in the Fabaceae, Piperaceae, Cannabaceae, and Moraceae families. These chalcones have been shown to be promising lead antitumor-chemopreventive drugs by three different activities: antioxidants, cytotoxic and apoptosis inducers. In the recent years, SAR (structure-activity relationship) has contributed towards the improvement of anticancer properties of chalcones by substituting aryl rings and introducing heterocyclic moieties. This review summarizes the anticancer activities shown by natural chalcones and the SAR and describes how different chemical moiety modifications could lead them to be therapeutically useful in the treatment of cancer.
Keywords: Apoptosis, cancer, chalcone, chemoprevention, flavonoid, synthesis, tubulin.
Current Medicinal Chemistry
Title:Chalcones as Promising Lead Compounds on Cancer Therapy
Volume: 22 Issue: 30
Author(s): Antonio J. Leon-Gonzalez, Nuria Acero, Dolores Munoz-Mingarro, Inmaculada Navarro and Carmen Martin-Cordero
Affiliation:
Keywords: Apoptosis, cancer, chalcone, chemoprevention, flavonoid, synthesis, tubulin.
Abstract: Chalcones constitute a group of phenolic compounds that command an increasing interest on cancer research. Natural chalcones are widespread through the plant kingdom. The most abundant and investigated chalcones are isoliquiritigenin, flavokawain and xanthohumol, which are present in the Fabaceae, Piperaceae, Cannabaceae, and Moraceae families. These chalcones have been shown to be promising lead antitumor-chemopreventive drugs by three different activities: antioxidants, cytotoxic and apoptosis inducers. In the recent years, SAR (structure-activity relationship) has contributed towards the improvement of anticancer properties of chalcones by substituting aryl rings and introducing heterocyclic moieties. This review summarizes the anticancer activities shown by natural chalcones and the SAR and describes how different chemical moiety modifications could lead them to be therapeutically useful in the treatment of cancer.
Export Options
About this article
Cite this article as:
Leon-Gonzalez J. Antonio, Acero Nuria, Munoz-Mingarro Dolores, Navarro Inmaculada and Martin-Cordero Carmen, Chalcones as Promising Lead Compounds on Cancer Therapy, Current Medicinal Chemistry 2015; 22 (30) . https://dx.doi.org/10.2174/0929867322666150729114829
DOI https://dx.doi.org/10.2174/0929867322666150729114829 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [ Vitamin D and its Binding Protein: Challenges and Opportunities for Drug Research Guest Editor: Dr. Hubert Maehr ]
Current Topics in Medicinal Chemistry Chitosan Nanoparticles for Melanoma Cancer Treatment by Photodynamic Therapy and Electrochemotherapy Using Aminolevulinic Acid Derivatives
Current Medicinal Chemistry Modulation of Porcine (Sus scrofa domestica) and Pheasant (Phasianus colchicus) Carbonyl Reducing Enzymes by Anthelmintic Therapy with Flubendazole
Drug Metabolism Letters The Anti-Cancer Charm of Flavonoids: A Cup-of-Tea Will Do!
Recent Patents on Anti-Cancer Drug Discovery Role of Radiopharmaceuticals in Development of Inhaled Drugs
Current Pharmaceutical Design The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology Nuclear Imaging of Prostate Cancer with Gastrin-Releasing-Peptide- Receptor Targeted Radiopharmaceuticals
Current Pharmaceutical Design Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Nanosponges Encapsulated Phytochemicals for Targeting Cancer: A Review
Current Drug Targets Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry Transforming Growth Factor-β Signaling in Motor Neuron Diseases
Current Molecular Medicine Flavonoids in Neurodegeneration: Limitations and Strategies to Cross CNS Barriers
Current Medicinal Chemistry Disulfiram's Anticancer Activity: Evidence and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Enzymes Metabolizing Aristolochic Acid and their Contribution to the Development of Aristolochic Acid Nephropathy and Urothelial Cancer
Current Drug Metabolism Preface [ Hot Topic: Radiation Oncology as Mainstay of Modern Cancer Medicine (Guest Editors: Claus Belka & Verena Jendrossek)]
Current Medicinal Chemistry - Anti-Cancer Agents Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Nucleosides, a Valuable Chemical Marker for Quality Control in Traditional Chinese Medicine Cordyceps
Recent Patents on Biotechnology Betulinic Acid as a Potent and Complex Antitumor Phytochemical: A Minireview
Anti-Cancer Agents in Medicinal Chemistry